Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


27.09.2021

5 BJU Int
3 BMC Cancer
2 BMC Urol
1 Br J Cancer
5 Br J Radiol
1 Cancer
1 Cancer Lett
2 Cancer Res
1 Clin Cancer Res
2 Eur Radiol
8 Eur Urol
1 Hum Pathol
13 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 J Cell Physiol
1 J Magn Reson Imaging
1 J Nucl Med
6 J Urol
1 Magn Reson Med
1 Nat Rev Urol
1 PLoS One
1 Prog Urol
3 Prostate
3 Radiol Imaging Cancer
1 Radiology
1 Ther Adv Urol
5 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. TUTOLO M, Bruyneel L, Van der Aa F, Van Damme N, et al
    A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence.
    BJU Int. 2021;127:575-584.
    PubMed         Abstract available

  2. URKMEZ A, Ward JF, Choi H, Troncoso P, et al
    Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2021;127:524-527.
    PubMed        

  3. INOUE S, Hayashi T, Teishima J, Matsubara A, et al
    Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2021;127:560-566.
    PubMed         Abstract available

  4. BARRETT T, Padhani AR, Patel A, Ahmed HU, et al
    Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.
    BJU Int. 2021;127:304-306.
    PubMed        

  5. NYBERG M, Sjoberg DD, Carlsson SV, Wilderang U, et al
    Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial.
    BJU Int. 2021;127:361-368.
    PubMed         Abstract available


    BMC Cancer

  6. JAHNEN M, Mynzak E, Meissner VH, Schiele S, et al
    Diversity of cancer-related identities in long-term prostate cancer survivors after radical prostatectomy.
    BMC Cancer. 2021;21:1041.
    PubMed         Abstract available

  7. LI Q, Xiao M, Shi Y, Hu J, et al
    eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
    BMC Cancer. 2021;21:1022.
    PubMed         Abstract available

  8. SHIINA M, Hashimoto Y, Kulkarni P, Dasgupta P, et al
    Role of miR-182/PDCD4 axis in aggressive behavior of prostate cancer in the African Americans.
    BMC Cancer. 2021;21:1028.
    PubMed         Abstract available


    BMC Urol

  9. KAKUTANI S, Takeshima Y, Yamada Y, Fujimura T, et al
    Clinical significance and risk factors of urethrovesical anastomotic urinary leakage following robot-assisted radical prostatectomy: a multi-institutional study.
    BMC Urol. 2021;21:75.
    PubMed         Abstract available

  10. KIM JY, Yu JH, Sung LH, Cho DY, et al
    Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
    BMC Urol. 2021;21:131.
    PubMed         Abstract available


    Br J Cancer

  11. YU H, Xie M, Meng Z, Lo CY, et al
    Endolysosomal ion channel MCOLN2 (Mucolipin-2) promotes prostate cancer progression via IL-1beta/NF-kappaB pathway.
    Br J Cancer. 2021 Sep 21. pii: 10.1038/s41416-021-01537.
    PubMed         Abstract available


    Br J Radiol

  12. WU YY, Fan KH
    Proton therapy for prostate cancer: current state and future perspectives.
    Br J Radiol. 2021 Sep 24:20210670. doi: 10.1259/bjr.20210670.
    PubMed         Abstract available

  13. TAMADA T, Kido A, Ueda Y, Takeuchi M, et al
    Clinical impact of ultra-high b-value (3000 s/mm(2)) diffusion-weighted magnetic resonance imaging in prostate cancer at 3T: comparison with b-value of 2000 s/mm(2).
    Br J Radiol. 2021 Sep 24:20210465. doi: 10.1259/bjr.20210465.
    PubMed         Abstract available

  14. UENO Y, Tamada T, Sofue K, Murakami T, et al
    Diffusion and quantification of diffusion of prostate cancer.
    Br J Radiol. 2021 Sep 19:20210653. doi: 10.1259/bjr.20210653.
    PubMed         Abstract available

  15. ZAPATERO A, Roch M, Castro Tejero P, Buchser D, et al
    MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
    Br J Radiol. 2021 Sep 19:20210683. doi: 10.1259/bjr.20210683.
    PubMed         Abstract available

  16. SUSHENTSEV N, Caglic I, Rundo L, Kozlov V, et al
    Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression.
    Br J Radiol. 2021 Sep 19:20210842. doi: 10.1259/bjr.20210842.
    PubMed         Abstract available


    Cancer

  17. NABI J, Tully KH, Cole AP, Marchese M, et al
    Access denied: The relationship between patient insurance status and access to high-volume hospitals.
    Cancer. 2021;127:577-585.
    PubMed         Abstract available


    Cancer Lett

  18. TIAN P, Zhong M, Wei GH
    Mechanistic insights into genetic susceptibility to prostate cancer.
    Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00472.
    PubMed         Abstract available


    Cancer Res

  19. LIU Z, Guo C, Das SK, Yu X, et al
    Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
    Cancer Res. 2021;81:2429-2441.
    PubMed         Abstract available

  20. RAHMAN NIA, Sato A, Tsevelnorov K, Shimizu A, et al
    Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth.
    Cancer Res. 2021;81:2318-2331.
    PubMed         Abstract available


    Clin Cancer Res

  21. MIZUNO K, Sumiyoshi T, Okegawa T, Terada N, et al
    Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-2328.
    PubMed         Abstract available


    Eur Radiol

  22. HINZPETER R, Baumann L, Guggenberger R, Huellner M, et al
    Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.
    Eur Radiol. 2021 Sep 24. pii: 10.1007/s00330-021-08245.
    PubMed         Abstract available

  23. CUOCOLO R, Stanzione A, Faletti R, Gatti M, et al
    MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study.
    Eur Radiol. 2021;31:7575-7583.
    PubMed         Abstract available


    Eur Urol

  24. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    PubMed        

  25. HAGENS MJ, van Leeuwen PJ
    A Future Prebiopsy Imaging-guided Pathway to Safely Omit Systematic Biopsies and Prevent Diagnosis of Indolent Prostate Cancer.
    Eur Urol. 2021 Sep 21. pii: S0302-2838(21)02002.
    PubMed        

  26. LANTZ A, Bock D, Akre O, Angenete E, et al
    Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up.
    Eur Urol. 2021 Sep 15. pii: S0302-2838(21)01928.
    PubMed         Abstract available

  27. GHALI F, Kane CJ
    Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality.
    Eur Urol. 2021 Sep 14. pii: S0302-2838(21)01999.
    PubMed        

  28. HU JC, Basourakos SP, Futterer J
    Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.
    Eur Urol. 2021;79:167-169.
    PubMed         Abstract available

  29. ALAN MCNEILL S, Gallagher KM, Clyde D
    Re: A Biochemical Definition of Cure After Brachytherapy for Prostate Cancer.
    Eur Urol. 2021 Sep 13. pii: S0302-2838(21)01995.
    PubMed        

  30. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    PubMed        

  31. RANASINGHE W, Shapiro DD, Hwang H, Wang X, et al
    Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.
    Eur Urol. 2021;79:298-306.
    PubMed         Abstract available


    Hum Pathol

  32. CHEN Z, Pham H, Abreu A, Amin MB, et al
    Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason Score 7 prostate cancer with Cribriform Gleason Pattern 4.
    Hum Pathol. 2021 Sep 17. pii: S0046-8177(21)00163.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  33. ENNIS RD, Vapiwala N
    The Fallacy of the Consultation and Informed Consent Process in Radiation Oncology Through the Lens of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111:643-646.
    PubMed        

  34. LEITE ETT, Ramos CCA, Moraes FY
    In Reply to Fiorino et al.
    Int J Radiat Oncol Biol Phys. 2021;110:1549-1550.
    PubMed        

  35. VAN DAMS R, Jiang NY, Fuller DB, Loblaw A, et al
    Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.
    Int J Radiat Oncol Biol Phys. 2021;110:731-737.
    PubMed         Abstract available

  36. RANS K, De Meerleer G, Joniau S, Baten A, et al
    In Regard to Zelefsky et al.
    Int J Radiat Oncol Biol Phys. 2021;110:910-911.
    PubMed        

  37. WALSHAW RC, Hoskin PJ, Choudhury A
    Can Hypofractionation and Immune Modulation Coexist?
    Int J Radiat Oncol Biol Phys. 2021;110:742-744.
    PubMed        

  38. WALLIS CJD, Klotz L, Satkunasivam R, Klaassen Z, et al
    Not So "Active" Surveillance.
    Int J Radiat Oncol Biol Phys. 2021;110:716-717.
    PubMed        

  39. SHORTALL J, Palma G, Mistry H, Vasquez Osorio E, et al
    Flogging a Dead Salmon? Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Int J Radiat Oncol Biol Phys. 2021;110:696-699.
    PubMed        

  40. CHEN RC
    A Trans-Atlantic Voyage of Extended ADT With Local Radiation.
    Int J Radiat Oncol Biol Phys. 2021;110:633.
    PubMed        

  41. ARAI TJ, Yang DM, Campbell JW 3rd, Chiu T, et al
    Oxygen-Sensitive MRI: A Predictive Imaging Biomarker for Tumor Radiation Response?
    Int J Radiat Oncol Biol Phys. 2021;110:1519-1529.
    PubMed         Abstract available

  42. PARKER C
    Timing of Postoperative Radiation Therapy After Radical Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2021;110:1132-1134.
    PubMed        

  43. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
    Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
    Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
    PubMed         Abstract available

  44. YANG Y, Vargas CE, Bhangoo RS, Wong WW, et al
    Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT).
    Int J Radiat Oncol Biol Phys. 2021;110:1189-1199.
    PubMed         Abstract available

  45. HSU IC, Rodgers JP, Shinohara K, Purdy J, et al
    Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
    Int J Radiat Oncol Biol Phys. 2021;110:700-707.
    PubMed         Abstract available


    Int J Urol

  46. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14701.
    PubMed         Abstract available

  47. SHIOTA M, Blas L, Kobayashi S, Matsumoto T, et al
    Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14702.
    PubMed         Abstract available


    J Cell Physiol

  48. SHI B, Qi J
    The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    J Cell Physiol. 2021;236:2620-2630.
    PubMed         Abstract available


    J Magn Reson Imaging

  49. MAIER SE, Wallstrom J, Langkilde F, Johansson J, et al
    Prostate Cancer Diffusion-Weighted Magnetic Resonance Imaging: Does the Choice of Diffusion-Weighting Level Matter?
    J Magn Reson Imaging. 2021 Sep 18. doi: 10.1002/jmri.27895.
    PubMed         Abstract available


    J Nucl Med

  50. FEUERECKER B, Chantadisai M, Allmann A, Tauber R, et al
    Pre-therapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262671. doi: 10.2967/jnumed.121.262671.
    PubMed         Abstract available


    J Urol

  51. MARTINI A, Soeterik TFW, Haverdings H, Rahota RG, et al
    An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
    J Urol. 2021 Sep 22:101097JU0000000000002205. doi: 10.1097/JU.0000000000002205.
    PubMed         Abstract available

  52. XUE AL, Kalapara AA, Ballok ZE, Levy SM, et al
    (68)Ga-PSMA PET SUVmax as a Predictor of Gleason Pattern 4 and Pathologic Upgrading in Intermediate Risk Prostate Cancer.
    J Urol. 2021 Sep 21:101097JU0000000000002254. doi: 10.1097/JU.0000000000002254.
    PubMed         Abstract available

  53. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
    Statin Use and Lower Urinary Tract Symptoms (LUTS) Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    J Urol. 2021 Sep 21:101097JU0000000000002199. doi: 10.1097/JU.0000000000002199.
    PubMed         Abstract available

  54. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
    Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter.
    J Urol. 2021 Sep 16:101097JU0000000000002245. doi: 10.1097/JU.0000000000002245.
    PubMed        

  55. CHIERIGO F, Wenzel M, Wurnschimmel C, Flammia RS, et al
    Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
    J Urol. 2021 Sep 24:101097JU0000000000002250. doi: 10.1097/JU.0000000000002250.
    PubMed         Abstract available

  56. LEAPMAN MS, Stone K, Wadia R, Park LS, et al
    Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.
    J Urol. 2021 Sep 24:101097JU0000000000002249. doi: 10.1097/JU.0000000000002249.
    PubMed         Abstract available


    Magn Reson Med

  57. TAYARI N, Wright AJ, Heerschap A
    Absolute choline tissue concentration mapping for prostate cancer localization and characterization using 3D (1) H MRSI without water-signal suppression.
    Magn Reson Med. 2021 Sep 23. doi: 10.1002/mrm.29012.
    PubMed         Abstract available


    Nat Rev Urol

  58. DEVOS G, Devlies W, De Meerleer G, Baldewijns M, et al
    Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.
    Nat Rev Urol. 2021 Sep 15. pii: 10.1038/s41585-021-00514.
    PubMed         Abstract available


    PLoS One

  59. CIMORELLI M, Nieuwland R, Varga Z, van der Pol E, et al
    Standardized procedure to measure the size distribution of extracellular vesicles together with other particles in biofluids with microfluidic resistive pulse sensing.
    PLoS One. 2021;16:e0249603.
    PubMed         Abstract available


    Prog Urol

  60. AOUN F, Mjaess G, Abi Tayeh G, Sarkis J, et al
    Focal therapy for prostate cancer: Making the punishment fit the crime.
    Prog Urol. 2021 Sep 16. pii: S1166-7087(21)00215.
    PubMed         Abstract available


    Prostate

  61. YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
    Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
    PubMed         Abstract available

  62. YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
    Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
    Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
    PubMed         Abstract available

  63. HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
    SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
    PubMed         Abstract available


    Radiol Imaging Cancer

  64. COSTA DN, Cai Q, Xi Y, Recchimuzzi DZ, et al
    Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies.
    Radiol Imaging Cancer. 2021;3:e200123.
    PubMed         Abstract available

  65. LIU X
    MRI-guided Focal Treatment of Prostate Cancer.
    Radiol Imaging Cancer. 2021;3:e219022.
    PubMed        

  66. BARDIS M, Houshyar R, Chantaduly C, Tran-Harding K, et al
    Segmentation of the Prostate Transition Zone and Peripheral Zone on MR Images with Deep Learning.
    Radiol Imaging Cancer. 2021;3:e200024.
    PubMed         Abstract available


    Radiology

  67. KANG SK, Mali RD, Prabhu V, Ferket BS, et al
    Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Radiology. 2021;301:E380.
    PubMed        


    Ther Adv Urol

  68. SERRANO DOMINGO JJ, Alonso Gordoa T, Lorca Alvaro J, Molina-Cerrillo J, et al
    The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
    Ther Adv Urol. 2021;13:17562872211043341.
    PubMed         Abstract available


    Urol Int

  69. APFELBECK M, Schlenker B, Chaloupka M, Stief CG, et al
    Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature.
    Urol Int. 2021;105.
    PubMed         Abstract available

  70. GOSSLER C, May M, Breyer J, Stojanoski G, et al
    High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection.
    Urol Int. 2021;105.
    PubMed         Abstract available

  71. XU B, Ma BL, Peng YJ, Zhang Q, et al
    Learning Curve of an Innovative "3-Port" Laparoscopic Radical Prostatectomy: A Single-Center Analysis from 2016 to 2019.
    Urol Int. 2021;105.
    PubMed         Abstract available

  72. SCHMITZ-DRAGER BJ, Muhlich S, Lange C, Benderska-Soder N, et al
    Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
    Urol Int. 2021;105.
    PubMed         Abstract available

  73. NAKANISHI Y, Ito M, Kataoka M, Ikuta S, et al
    Who Can Avoid Biopsy of Magnetic Resonance Imaging-Negative Lobes without Compromising Significant Cancer Detection among Men with Unilateral Magnetic Resonance Imaging-Positive Lobes?
    Urol Int. 2021;105.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: